Related Experiment Videos
Delayed percutaneous transluminal coronary angioplasty after acute myocardial infarction
1The Heart Institute, Kaplan Medical Center, Rehovot, Israel.
Insights
Delayed percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction significantly reduces mortality. This procedure is safe and beneficial for selected post-heart attack patients in the community.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- The efficacy of delayed percutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction (AMI) remains debated.
- Delayed PTCA is defined as occurring more than 12 hours from admission or after thrombolytic therapy.
Purpose of the Study:
- To compare the short- and long-term prognosis of patients undergoing delayed PTCA versus those who did not.
- To evaluate the safety and benefits of delayed PTCA in selected post-AMI patients.
Main Methods:
- A comparative study of 1940 consecutive patients post-AMI.
- 188 patients underwent delayed PTCA; outcomes were analyzed against a control group.
- Multivariate analysis was employed to adjust for confounding factors.
Main Results:
- Patients undergoing delayed PTCA were younger, more often male, and smokers, with fewer in-hospital complications.
- Crude 30-day and 1-year mortality rates were significantly lower in the delayed PTCA group (3% and 6%) compared to the no-PTCA group (14% and 21%).
- Adjusted analysis showed a 65% mortality risk reduction at 30 days (RR=0.35) and 50% at 1 year (RR=0.50) with delayed PTCA.
Conclusions:
- Delayed PTCA in selected post-AMI patients, based on clinical indication, is a safe and effective treatment strategy.
- The findings support the use of delayed PTCA to improve outcomes following acute myocardial infarction.
Abstract:
The value of delayed percutaneous transluminal coronary angioplasty (> 12 h from admission or after thrombolytic therapy) following acute myocardial infarction is controversial. We compared the short- and long-term prognosis of 1940 consecutive patients after acute myocardial infarction, of whom 188 underwent delayed percutaneous transluminal coronary angioplasty. Delayed percutaneous transluminal coronary angioplasty was more frequently done in patients treated with thrombolysis (12%) than among patients excluded from thrombolytic therapy (8%; P=0.005). Patients in the delayed percutaneous transluminal coronary angioplasty group were younger, included more men and smokers and had less in-hospital complications in comparison to patients who did not undergo delayed percutaneous transluminal coronary angioplasty. The crude 30-day and 1-year mortality rates were 3 and 6% among patients who underwent percutaneous transluminal coronary angioplasty vs. 14 and 21% (P<0.01 for each) among those without percutaneous transluminal coronary angioplasty, respectively. After multivariate analysis adjusted for confounding factors, delayed percutaneous transluminal coronary angioplasty was associated with 65 (RR=0.35; 90% CI 0.14-0.88) and 50% (RR=0.50; 90% CI 0.27-0.92) mortality risk reduction after 30 days and 1 year, respectively. In conclusion, delayed percutaneous transluminal coronary angioplasty applied to selected post-myocardial infarction patients upon clinical indication is safe and beneficial for the treatment of acute myocardial infarction in the community.